logo
Thanks to bans and fees, there are fewer plastic bags littering beaches

Thanks to bans and fees, there are fewer plastic bags littering beaches

Fast Company3 hours ago

It turns out eliminating the 'paper or plastic' question through plastic bag regulation is effectively reducing the number of bags found in shoreline litter across the United States.
A new analysis of shoreline cleanup data finds that areas with plastic bag bans or consumer fees have fewer bags turning up in their litter. The research offers some of the strongest evidence yet that regulating plastic bag use makes a difference in reducing the amount of plastic waste in marine ecosystems.
A heightened threat to marine wildlife
'We find, largely, that all the regulations do show a decrease in plastic bag litter as a share of total litter on these shores,' says Kimberly Oremus, co-author of the research paper and an assistant professor of marine science and policy at the University of Delaware. The total reduction ranged between 25% and 47%, the study found.
About 20 metric tons of plastic end up in the environment each year, estimates the International Union for Conservation of Nature—that amounts to over 2.4 kilograms of plastic for each person on Earth.
Plastic bags are particularly prevalent in marine ecosystems. They are very difficult to recycle and, because they are lightweight and have a large surface area for wind to catch, they blow out of the trash and into the environment at higher rates than other plastic items, says Erin Murphy, the ocean plastics science and research manager at the environmental advocacy nonprofit Ocean Conservancy, who was not involved in the research. She added that in 2024 alone, the conservancy's International Coastal Cleanup volunteers gathered up more than a million plastic bags.
In addition to getting into the environment at high rates, plastic bags also pose a heightened threat to marine wildlife. Wildlife can become entangled in or smothered by these bags or can mistake them for food, like jellyfish, a favorite among many species. These interactions with plastic can lead to the deaths of endangered and common animals alike and can even contribute to broader population declines.
Counting the plastic bags
'One big challenge in studying the effects and regulations of plastics is actually measuring this pollutant in the environment,' says Anna Papp, co-author of the research paper.
To overcome this challenge, the study used crowd-funded data from beach cleanups. The data was collected by the Ocean Conservancy as part of their Trash Information and Data for Education and Solutions (TIDES) project. Nearly 19 million people have participated in the data collection worldwide.
The study also examined plastic bag policies at various geographical scales between 2017 and 2023. The earliest plastic bag policies in the U.S. were implemented around 2007, researchers say, but an uptick in the mid-2010s more directly led to the policies analyzed in the study.
While the data provides insight into how the share of plastic bags found among shoreline litter has changed due to policy measures, an important caveat remains: Plastic litter has been increasing overall. Plastic production doubled from 234 million to 460 million tons between 2000 and 2019—and without mitigation, it is only expected to rise, according to a recent report from the French-based Organisation for Economic Co-operation and Development (OECD).
Some regulations are better than others
Still, the researchers noted that not all regulations worked equally well. Total bans and consumer fees resulted in greater decreases than partial bans, which still allow businesses to use thicker, potentially reusable plastic bags. The researchers also found that regulation was most effective in places that had a high baseline of plastic bag litter before the bans or fees went into place.
The study data seems to indicate that consumer fees were the most effective option for mitigating plastic bag litter, though the paper's authors say more research is needed to confirm this finding.
'These policies are effective, but they're not a panacea for all plastic litter,' Oremus said. 'Anyone who's looking at regulations for plastic broadly needs to think beyond just the consumption side of plastic.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet

Yahoo

time26 minutes ago

  • Yahoo

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet

Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2 PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in The Lancet.1 In a phase 1b/2a clinical trial of 125 adults with overweight or obesity, once-weekly subcutaneous amycretin appeared to be safe and tolerable in trial participants, who also achieved significantly greater weight loss across the full range of doses investigated versus placebo.1 A related phase 1 trial of once-daily oral amycretin in adults with obesity or overweight also showed that treatment was safe and tolerable with an observed reduction in body weight compared to placebo.2 No weight loss plateau was observed in either trial at the end of the respective treatment durations.1,2 Data on subcutaneous amycretin is scheduled to be presented on Sunday, June 22nd, during a late-breaking poster session at the American Diabetes Association's® (ADA) 85th Scientific Sessions.1 "We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management. At Novo Nordisk, we understand that addressing obesity is a complex challenge that many patients face. These results reflect our robust pipeline in obesity, our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals," said Martin Holst Lange, executive vice president for Development at Novo Nordisk. "We remain steadfast in our mission to discover and develop therapies that can have a meaningful impact in the lives of those affected by obesity." Results from the phase 1b/2a trial of subcutaneous amycretin showed treatment-emergent adverse events (TEAEs) were mild or moderate in severity and increased in frequency in a dose-dependent manner. The most frequent reported TEAEs were gastrointestinal in nature. Compared to placebo, participants receiving amycretin observed greater weight loss across the full range of doses investigated.1 Subcutaneous amycretin at multiple doses demonstrated greater weight reduction than placebo at the end of the trial. Participants who received the highest doses (up to 60 mg) reported body weight reductions of up to 24.3% versus 1.1% with placebo after 36 weeks of treatment. Results from this first-in-human phase 1b/2a study support further investigation of potential weight-loss efficacy of amycretin. Results from the published phase 1 trial of oral amycretin showed that the most common TEAEs were related to gastrointestinal symptoms (mainly nausea and vomiting) and decreased appetite; these were most frequent for the higher doses. Trial participants receiving the study treatment demonstrated significantly greater weight loss across the full range of doses investigated versus the placebo group.2 Exploratory results showed participants taking 100 mg per day of oral amycretin achieved a mean weight loss of 13.1% versus 1.2% with placebo after 12 weeks.2 Based on these phase 1 results, longer evaluation with more participants is warranted to substantiate the full efficacy findings of oral amycretin on body weight reductions and changes in metabolic parameters. Novo Nordisk will advance both subcutaneous and oral amycretin formulations straight to phase 3 development for weight management based on these and other completed clinical studies, as well as feedback received from regulatory authorities. About amycretinAmycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is under investigation for oral and subcutaneous administration, and is not approved in the US for weight loss. About the phase 1b/2a subcutaneous amycretin trialThe phase 1b/2a trial was a randomized, placebo-controlled, single-center, double-blinded study of 125 participants assessing the safety, tolerability, pharmacokinetics, and effects on body weight after subcutaneous administration of amycretin in people with overweight or obesity.1 Adults with a body mass index of 27-39.9kg/m2 and glycated hemoglobin (HbA1c) <6.5% were eligible for the trial.1 The trial was conducted in 5 parts: a single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B).1 Lastly, in the multiple ascending dose – dose response parts, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).1 About the phase 1 oral amycretin trial The phase 1 single-center, randomized, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (Part A) and multiple ascending doses (Part B, 10 days of treatment; Part C/D, 12 weeks of treatment) of 144 adult participants with overweight or obesity.2 The primary endpoint was the number of treatment-emergent adverse events (TEAEs) observed in the trial. The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.2 About obesityObesity is a serious chronic, progressive, and complex disease that requires long-term management.3-5 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.3,5 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.6,7 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.8,9 In the US, about 40% of adults live with obesity.10 About Novo NordiskNovo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information Media:Liz Skrbkova (US)+1 609 917 0632USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Investors:Frederik Taylor Pitter (US)+1 609 613 0568fptr@ Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@ Sina Meyer (Global)+45 3079 6656 azey@ Ida Schaap Melvold (Global)+45 3077 5649 idmg@ Max Ung (Global)+45 3077 6414mxun@ References Dahl K, Toubro S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: Results of a randomised, controlled, phase 1b/2a study. The Lancet. Published online: June 20, 2025. Gasiorek A, Heydorn A, Gabery S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, randomised, placebo-controlled study. The Lancet. Published online: June 20, 2025. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61-69. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Rev. 2017;18(7):715-723. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1-203. Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: June 2025. Available at: World Obesity Federation. World Obesity Atlas 2023. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Why it matters. Last accessed: June 2025. Available at: Centers for Disease Control and Prevention. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023. Last accessed June 2025. Available at: © 2025 Novo Nordisk All rights reserved. US25SEMO01477 June 2025 View original content to download multimedia: SOURCE NOVO NORDISK INC.

Switch to Water From Diet Sodas May Boost Diabetes Remission
Switch to Water From Diet Sodas May Boost Diabetes Remission

Medscape

time32 minutes ago

  • Medscape

Switch to Water From Diet Sodas May Boost Diabetes Remission

TOPLINE: Regularly substituting water for diet beverages contributed to greater weight loss and was associated with a twofold increase in the diabetes remission rate among women with type 2 diabetes (T2D) and obesity or overweight. METHODOLOGY: Diet sodas, despite being calorie-free, may affect the body differently from water, and their regular consumption is linked to potential health risks, including cardiovascular disease, T2D, and obesity. Researchers conducted an 18-month study to evaluate the effects of replacing diet beverages with water. The study included 81 adult women with T2D and obesity or overweight who participated in a weight-management program and regularly consumed diet beverages. Participants were randomly assigned to replace diet beverages with water or to maintain their usual intake of five diet drinks per week, consumed after lunch. All participants underwent a 6-month weight-loss program, followed by a 12-month maintenance program. TAKEAWAY: Women in the water group experienced a greater average weight loss (-6.82 ± 2.73 kg) than the diet beverage group (-4.85 ± 2.07 kg; P < .001). Diabetes remission was achieved by 90% of participants in the water group compared with 45% of those in the diet beverage group (P < .0001). Significant improvements were noted in BMI, fasting glucose, postprandial glucose, insulin, triglyceride levels, and insulin resistance in the water group. IN PRACTICE: "These findings challenge a common belief in the US that diet drinks have no potential negative effects for managing weight and blood sugar," Hamid R. Farshchi, MD, PhD, CEO of the digital platform D2Type, said in a press release. "However, with most of the women in the water group achieving diabetes remission, our study highlights the importance of promoting water, not just low-calorie alternatives, as part of effective diabetes and weight management. It's a small change with the potential for a big impact on long-term health outcomes." SOURCE: The study was led by Hamid R. Farshchi, MD, PhD, of D2Type, and former associate professor at the University of Nottingham, School of Life Sciences. It was presented as a poster on June 22, 2025, at the 85th Scientific Sessions - American Diabetes Association held at the McCormick Place Convention Center, Chicago (June 20-23, 2025). LIMITATIONS: No limitations were discussed in the press release. DISCLOSURES: No disclosures or conflict-of-interest statements were provided. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Smartphone-Based Home Albuminuria Testing Boosts Screening
Smartphone-Based Home Albuminuria Testing Boosts Screening

Medscape

time32 minutes ago

  • Medscape

Smartphone-Based Home Albuminuria Testing Boosts Screening

TOPLINE: Screening for albuminuria, a key marker of cardiorenal risk, remains inadequate among patients with diabetes or hypertension. A smartphone-enabled home testing solution, evaluated in 4000 adults, effectively increased screening rates and enabled early diagnosis of kidney disease. METHODOLOGY: Regular albuminuria testing is recommended in high-risk patients with diabetes or hypertension to enable early detection and timely intervention for kidney and cardiovascular complications; however, screening levels remains suboptimal. Researchers randomly selected 4000 adults (mean age, 61 years; 49% women; 93% White) from a large Central Pennsylvania healthcare system who had not undergone albumin-creatinine ratio testing in the previous 12 months; half the patients in the cohort had hypertension without diabetes, and the remaining half had diabetes. Patients were provided with Minuteful Kidney, an FDA-cleared, smartphone-enabled home albuminuria screening kit. Results were delivered to participants via a smartphone application and to healthcare providers through electronic health records. The intervention group was propensity score-matched with a control group receiving usual care. TAKEAWAY: Completion rates for any albumin-creatinine ratio testing were significantly higher in the intervention group than in the control group (53.1% vs 21.2%; P < .001). The impact of the intervention on albumin-creatinine ratio testing completion was more pronounced among patients with hypertension without diabetes (completion rates, 53.4% in the intervention group vs 12.5% in the control group) than among those with diabetes (completion rates, 52.7% vs 30.0%). Over 270 days of follow-up, patients tested with Minuteful Kidney had higher rates of new diagnoses of proteinuria or kidney disease (4.0% vs 2.2%; P < .001). Patients with an abnormal albumin-creatinine ratio on the home-based test demonstrated greater engagement with primary care and nephrology services and were more likely to receive prescriptions for renin-angiotensin-aldosterone system inhibitors than were those with normal results. IN PRACTICE: "A smartphone-enabled home albuminuria test is effective in increasing albuminuria screening and diagnosis of kidney disease among high-risk individuals," the authors concluded. SOURCE: The study was led by Waleed Zafar in Danville, Pennsylvania. It was presented on June 20, 2025, at the 85th Scientific Sessions – American Diabetes Association held at the McCormick Place Convention Center, Chicago. LIMITATIONS: The abstract did not discuss any limitations. DISCLOSURES: Two authors disclosed receiving research support from various pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store